2 weeks Ago By ABMN Staff
Maverick Capital Ltd. lifted its holdings in Novo Nordisk A/S ( NYSE:NVO – Free Report ) by 272.9% in the second quarter, HoldingsChannel.
com reports. The institutional investor owned 7,849 shares of the company’s stock after purchasing an additional 5,744 shares during the quarter. Maverick Capital Ltd.
’s holdings in Novo Nordisk A/S were worth $1,120,000 at the end of the most recent reporting period. Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Aveo Capital Partners LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $205,000.
9258 Wealth Management LLC lifted its holdings in Novo Nordisk A/S by 4.0% during the 4th quarter. 9258 Wealth Management LLC now owns 2,513 shares of the company’s stock worth $260,000 after buying an additional 97 shares in the last quarter.
Rollins Financial boosted its position in Novo Nordisk A/S by 10.4% in the 4th quarter. Rollins Financial now owns 3,894 shares of the company’s stock valued at $403,000 after buying an additional 368 shares during the last quarter.
Charles Schwab Investment Management Inc. increased its stake in shares of Novo Nordisk A/S by 38.1% in the 4th quarter.
Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock valued at $9,781,000 after buying an additional 26,067 shares during the period. Finally, Gryphon Financial Partners LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $237,000.
Institutional investors and hedge funds own 11.54% of the company’s stock. Novo Nordisk A/S Trading Down 2.
8 % Shares of NYSE NVO opened at $120.76 on Friday. Novo Nordisk A/S has a twelve month low of $86.
96 and a twelve month high of $148.15. The stock has a market cap of $541.
91 billion, a price-to-earnings ratio of 41.64, a P/E/G ratio of 1.35 and a beta of 0.
42. The company has a quick ratio of 0.75, a current ratio of 0.
94 and a debt-to-equity ratio of 0.46. The company’s fifty day moving average is $131.
97 and its 200-day moving average is $133.00. Novo Nordisk A/S Cuts Dividend The business also recently announced a semi-annual dividend, which was paid on Monday, August 26th.
Shareholders of record on Friday, August 16th were issued a dividend of $0.5126 per share. The ex-dividend date of this dividend was Friday, August 16th.
This represents a yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 24.
83%. Analyst Ratings Changes A number of research analysts have issued reports on NVO shares. Cantor Fitzgerald restated an “overweight” rating and set a $160.
00 target price on shares of Novo Nordisk A/S in a research report on Monday, September 16th. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $170.00 to $160.
00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 18th.
Finally, Argus raised their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, June 10th.
One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $145.
17. Check Out Our Latest Research Report on NVO About Novo Nordisk A/S ( Free Report ) Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Articles Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S ( NYSE:NVO – Free Report ). Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.
com's FREE daily email newsletter ..
